Back to top
more

Amgen Inc. (AMGN)

(Delayed Data from NSDQ)

$255.71 USD

255.71
2,706,349

+0.58 (0.23%)

Updated Apr 16, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (196 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Stock Market News for Apr 16, 2021

Benchmark hit new records on Thursday as rebound in consumer spending and a buoyant jobs market attested economic recovery along with better-than-expected Q1 earnings reports.

Sheraz Mian headshot

Top Stock Reports for Abbott, salesforce & BHP

Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), salesforce.com (CRM), and BHP Group (BHP).

AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis

AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.

Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

Style Box ETF report for DEF

Sheraz Mian headshot

Top Research Reports for JPMorgan, Verizon & Chevron

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Verizon Communications (VZ), and Chevron (CVX).

AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.

Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion

Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.

Amgen (AMGN) to Boost Inflammation Pipeline With Rodeo Buyout

Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.

Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL (Revised)

FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.

Merck (MRK) Keytruda Gets CHMP Nod for First-Line Bladder Cancer

Merck (MRK) is seeking approval for label expansion of Keytruda in Europe to include first-line treatment of certain patients with advanced or metastatic urothelial carcinoma.

Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD

Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.

Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL

FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.

Merck (MRK) Gets FDA Nod for Keytruda in Esophageal Cancer

The FDA approves Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy, for the first-line treatment of esophageal and gastroesophageal junction carcinoma.

Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study

Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.

AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months.

Merck (MRK) VHL-Linked Kidney Cancer Drug Gets FDA Priority Tag

The FDA grants Merck's (MRK) NDA for belzutifan priority review status to treat von Hippel-Lindau disease-associated renal-cell carcinoma.

The Zacks Analyst Blog Highlights: NIKE, Broadcom, Amgen, BlackRock and Estee Lauder

The Zacks Analyst Blog Highlights: NIKE, Broadcom, Amgen, BlackRock and Estee Lauder

Sheraz Mian headshot

Top Research Reports for Nike, Broadcom & Amgen

Today's Research Daily features new research reports on 16 major stocks, including NIKE (NKE), Broadcom (AVGO), and Amgen (AMGN).

Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).

Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout

Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.

Sweta Killa headshot

ETFs to Tap Amgen's Drive for Cancer Deal

Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.

Amgen (AMGN) Down 5.5% Since Last Earnings Report: Can It Rebound?

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat

Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.

Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).